COX-2 Class Is TARGET Of Critical Lancet Editorial

The TARGET study's mixed results on Novartis' Prexige prompted an editorial critique of the entire COX-2 inhibitor class of drugs

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet